524717 — Titan Biotech Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeMicro CapHigh Flyer

Annual income statement for Titan Biotech, fiscal year end - March 31st, INR millions except per share, conversion factor applied.

	2020 March 31st	2021 March 31st	R2022 March 31st	2023 March 31st	2024 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	PRESS
Standards:	IAS	IAS	IAS	IAS	—
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	794	1,422	1,235	1,440	1,641
Cost of Revenue
Gross Profit	401	777	550	606	885
Selling / General / Administrative Expenses
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	671	986	946	1,171	1,331
Operating Profit	123	436	289	269	310
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	104	427	290	281	315
Provision for Income Taxes
Net Income After Taxes	78.4	317	217	210	237
Minority Interest
Equity in Affiliates
Net Income Before Extraordinary Items
Net Income	70.7	303	217	248	249
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	70.7	303	217	248	249
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	8	37	26.2	30.1	30.1
Dividends per Share